Prostate Cancer

Prostate cancer is a highly hetero-geneous disease, with individual tumor cells having distinct genomic and pheno-typic characteristics, resulting in a great deal of variability in patients’ disease course.

Sumit K. Subudhi, MD, PhD, discusses the integration of antiandrogen agents in metastatic hormone-sensitive prostate cancer.

Investigators have made great strides in the development of radiopharmaceuticals for prostate cancer diagnostics, culminating in recent FDA approvals for the first prostate-specific membrane antigen–targeted radioligands, gallium 68–PSMA-11 and piflufolastat F 18, for the detection of disease recurrence and metastatic lesions.

Amado J. Zurita-Saavedra, MD, discusses moving therapies utilized in metastatic castration-resistant prostate cancer into the treatment of patients with metastatic hormone-sensitive prostate cancer.

Sumit K. Subudhi, MD, PhD, discusses future directions with immunotherapy in prostate cancer.

Andrew J. Armstrong, MD, discusses final overall survival data from the phase 3 randomized, double-blind, placebo-controlled ARCHES study of enzalutamide plus androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer presented at the European Society for Medical Oncology 2021 Congress.

Bilal A. Siddiqui, MD, discusses the current state of treatment in nonmetastatic castration-resistant prostate cancer.

Spanning metastatic non–small cell lung cancer, castration-resistant prostate cancer, and HER2-low breast cancer, here are 4 must-know clinical trials in Tennessee that community oncologists can now enroll their patients on.

Sumit K. Subudhi, MD, PhD, discusses the treatment of patients with nonmetastatic castration-resistant prostate cancer, as well as those with metastatic castration-naïve, hormone-sensitive, and castration-resistant prostate cancer.

Dr Zhang, MD, discusses cognitive assessment data from patients with metastatic castrate-resistant prostate cancer in the ODENZA trial receiving either darolutamide or enzalutamide that was presented at the European Society for Medical Oncology 2021 Annual Meeting.

The FDA has granted a priority review designation to a new drug application for lutetium-177-PSMA-617 for use in the treatment of patients with metastatic castration-resistant prostate cancer following androgen receptor pathway inhibition and taxane-based chemotherapy.

Olaparib in combination with abiraterone acetate demonstrated a significant and clinically meaningful improvement in radiographic progression-free survival vs abiraterone alone as a first-line treatment for patients with metastatic castration-resistant prostate cancer with or without homologous recombination repair gene mutations.

The FDA has authorized the marketing of Paige Prostate, an artificial intelligence–based software that was designed to help pathologists scan areas of the body for suspicious cancer as a supplement to the review of digitally-scanned slide images from prostate biopsies.

An in-depth discussion regarding experience treating nonmetastatic castration-resistant prostate cancer (CRPC) with apalutamide, enzalutamide, and darolutamide, and factors that impact treatment selection.

An overview of drug approvals for nonmetastatic castration-resistant prostate cancer (CRPC), and discussion regarding the potential utility of prostate-specific membrane antigen (PSMA) positron emission tomography (PET) to guide treatment decisions.

When added to androgen-deprivation therapy, abiraterone acetate and prednisolone with or without enzalutamide for 2 years improved survival outcomes in men with high-risk nonmetastatic prostate cancer.

Prednisone added to androgen-deprivation therapy plus docetaxel improved radiographic progression-free survival and overall survival in patients with de novo metastatic castration-sensitive prostate cancer.

A group of patients with metastatic castration resistant prostate cancer achieved favorable outcomes after receiving treatment with nivolumab in combination with rucaparib.

The phase 1b COSMIC-021 trial showed clinically meaningful activity with cabozantinib plus atezolizumab in patients with locally advanced or metastatic castration-resistant prostate cancer who have been previously treated, including patients with high-risk features.

Pembrolizumab plus olaparib may improve prostate-specific antigen response rate in patients with metastatic castration-resistant prostate cancer regardless of homologous recombination repair mutation status.

The safety profile of daralutamide in combination with androgen-deprivation therapy was similar to placebo in patients with nonmetastatic castration-resistant prostate cancer.

Treatment with darolutamide was associated with statistically significant benefits in episodic memory by computerized cognitive assessment compared with enzalutamide in patients with metastatic castration-resistant prostate cancer.

By studying olaparib-sensitive and -resistant cell lines, researchers were able to gather insights regarding PARP inhibitor treatment and resistance mechanisms, including the use of CDK inhibition as a potential means of overcoming PARP inhibitor resistance in prostate cancer.

Olaparib was still found to produce greater clinical benefit than enzalutamide or abiraterone acetate in patients with metastatic castration-resistant prostate cancer when the novel hormonal agents were examined separately rather than combined.

Neal D. Shore, MD, FACS, discusses the results of the randomized, open label, phase 2 ENACT trial in prostate cancer.